Compositions and methods for treatment of eye disorders
View Patent ↗The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
1. A method of treating dry eye disease in a subject in need thereof comprising administering to said subject an effective amount of an LFA-1 antagonist or its pharmaceutically acceptable salts or esters, wherein said LFA-1 antagonist is
and wherein the subject does not have Sjogren's syndrome.
2. The method according to claim 1 , wherein said administration comprises topical administration of said compound via a carrier vehicle selected from a group consisting of liquid drops, liquid wash, gel, ointment, spray, and liposome.
3. The method according to claim 2 , wherein said topical administration comprises infusion of said compound to an eye of said subject via a device selected from the group consisting of a pump-catheter system, a continuous or selective release device, and a contact lens.
4. The method according to claim 1 , wherein said administration involves systemically administering a liquid or liquid suspension of said compound via nose drops or nasal spray or nebulized liquid to oral or nasopharyngeal airways of said subject, such that an effective amount of said compound contacts one or more of the lacrimal gland, conjunctival tissue, tears, or ocular surface of the eye of said subject.
5. The method according to claim 1 , wherein said administration involves administering an oral form of said compound, such that an effective amount of said compound contacts one or more of the lacrimal gland, conjunctival tissue, tears, or ocular surface of the eye of said subject via systemic absorption and circulation.
6. The method according to claim 1 , wherein said administration is accomplished by administering an injectable form of said compound, such that an effective amount of said compound contacts one or more of the lacrimal tissues, conjunctival tissue, tears, or ocular surface of the eye of said subject via systemic absorption and circulation.
7. The method according to claim 1 , wherein said administration is accomplished by administering a suppository form of said compound, such that an effective amount of said compound contacts one or more of the lacrimal tissues, conjunctival tissue, tears, or ocular surface of the eye of said subject via systemic absorption and circulation.
8. The method according to claim 1 , wherein said administration is accomplished by administering an intraocular instillation of a gel, cream, powder, foam, crystals, liposomes, spray or liquid suspension form of said compound.
9. The method according to claim 1 , wherein said compound is administered to the ocular surfaces of said subject in an amount sufficient to achieve concentrations thereof of from about 1×10 −7 to about 1×10 −1 moles/liter.
10. A method of treating dry eye disorder in a subject in need thereof comprising administering to an eye of said subject an effective amount of a pharmaceutical composition comprising an LFA-1 antagonist and/or its pharmaceutically acceptable salts or esters, wherein said LFA-1 antagonist is
whereby said administration is effective in promoting tear secretion or mucin production in said eye in said subject, and wherein the subject does not have Sjogren's syndrome.
11. A method of treating dry eye disease in a subject comprising performing a dry eye diagnostic test on said subject; determining whether said subject suffers from a dry eye disease based on the results of said diagnostic step; and upon diagnosis of said dry eye disease, administering to said subject an effective amount of a lymphocyte function associated antigen-1 (LFA-1) antagonist or a pharmaceutically acceptable salt or ester thereof, wherein said LFA-1 antagonist is
and wherein the subject does not have Sjogren's syndrome.
12. The method of claim 11 wherein said diagnostic step is performed by imaging an eye of said subject or analysis of a biological sample of an eye of said subject.
13. The method according to claim 1 wherein said administration is via a sustained release insert or implant, subconjunctival injection, intraocular injection, periocular injection, retrobulbar injection, or intracameral injection.
14. The method according to claim 1 , wherein said administration involves delivery of a liquid or liquid suspension of said compound via nose drops or nasal spray or nebulized liquid to oral or nasopharyngeal airways of said subject, such that an effective amount of said compound contacts one or more of the lacrimal gland, conjunctival tissue, or ocular surface of the eye of said subject via nasolacrimal ducts.
15. The method according to claim 1 , wherein said administration is accomplished by administering an injectable form of said compound, such that a therapeutically effective amount of said compound contacts one or more of the lacrimal tissues, conjunctival tissue or ocular surface of the eye of said subject via local delivery.
16. The method according to claim 3 wherein said continuous or selective release device is an ocular insert or implant.
17. The method according to claim 3 wherein an effective amount of said compound is distributed regionally to one or more of the nose, nasal passages, and nasal cavity.
18. The method according to claim 16 wherein said continuous or selective release device comprises a biocompatible polymer.
19. The method according to claim 8 wherein said administration comprises controlled release of said compound from a biocompatible polymer.